Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab
Background and Objective: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the
orbital tissue is interleukin-6 (IL-6).
Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.
Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.
Conclusion: Tocilizumab could be an optional treatment in patients with TAO.
Methods: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up.
Results: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor.
Conclusion: Tocilizumab could be an optional treatment in patients with TAO.
Keywords: Graves' associated ophthalmopathy; IL-6; Thyroid-associated ophthalmopathy; extrathyroidal manifestation; infiltrating cytokines; tocilizumab
Document Type: Case Report
Publication date: 01 November 2018
- This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content